A perspective on the primary care of patients with behavior, mood, and thought disturbances: Clinical applications of olanzapine

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 3, Issue 5, 2001, Pages 195-205

  Hay, Donald P ^a   Hurley, Daniel J ^b   McGuire, Hillary C ^a   Hay, Linda K ^a  

^a ELI LILLY AND COMPANY   (United States)

^b TLC Care Professional Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52549110869     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v03n0502     Document Type: Article

References (83)

1. Olafsdottir M, Marcusson J. Diagnosis of dementia at the primary care level. Acta Neurol Scand Suppl 1996;93:58-62
2. Conwell Y. Suicide in elderly patients. In: Schneider LS, Reynolds CFI, Lebowitz BD, et al, eds. Diagnosis and Treatment of Depression in Late Life. 1st ed. Washington, DC: American Psychiatric Press; 1994:397-418
3. Morris JC. Alzheimer's disease: a review of clinical assessment and management issues. Geriatrics 1997;52:S22-S25
4. Rovner BW, Kafonek S, Filipp L, et al. Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986;143:1446-1449
5. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48 (5. suppl):9-15
6. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996;44: 1078-1081
7. Coope B, Ballard C, Saad K, et al. The prevalence of depression in the carers of dementia sufferers. Int J Geriatr Psychiatry 1995;10:477-485
8. Wright LK, Hickey JV, Buckwalter KC, et al. Emotional and physical health of spouse caregivers of persons with Alzheimer's disease and stroke. J Adv Nurs 1999;30:552-563
9. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996;57(suppl 9):49-52
10. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
11. DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998;59(suppl 19): 9-17
12. Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis: pathways to care. Br J Psychiatry 1998;172:45-52
13. Tariot PN. Treatment of agitation in dementia. J Clin Psychiatry 1999;60 (suppl 8):11-20
14. Franson K, Chelsey D. Beta-blockers, benzodiazepines, and other miscellaneous agents. In: Hay DP, Klein D, Hay L, et al. eds. A Practical Guide to the Diagnosis and Management of Agitation in Patients With Dementia. In press
15. Ancill R, Carlyle R, Liang R, et al. Agitation in the demented elderly: a role for benzodiazepines? Int Clin Psychopharmacol 1991;6:141-146
16. Coccaro E, Kramer E, Zemishlany Z, et al. Pharmacologic treatment of non-cognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990;147:1640-1645
17. Cummings R, Miller P, Kelsey J, et al. Medications and multiple falls in elderly people: the St. Louis OASIS study. Age Ageing 1991 ;20:455-461
18. Goldney R. Paradoxical reaction to new minor tranquilizers. Med J Aust 1977;1:139-140
19. Janicak PG. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 1993;54(9, suppl):35-41
20. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001;9: 58-66
21. Depakote (divalproex sodium). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2001:427-437
22. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989;146:577-587
23. Currier GW. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000;61(suppl 14):21-26
24. Chengappa KN, Pollock BG, Parepally H, et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 2000;20:311-316
25. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000;22:195-214
26. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997;9:65-68
27. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995;15:24S-29S
28. DeDeyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955
29. Worrel JA, Marken PA, Beckman SE, et al. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000;57:238-258
30. Folks DG. Neuroleptics in the treatment of agitation in dementia. In: Hay DP, Klein D, Hay L, et al, eds. A Practical Guide to the Diagnosis and Management of Agitation in Patients with Dementia. In press
31. Geodon [package insert]. New York, NY: Pfizer Inc; 2001
32. Simpson G, Romano SJ, Horne RL, et al. Ziprasidone vs olanzapine in schizophrenia: results of a double-blind trial (abstract). Schizophr Res 2001;49(suppl 1-2):241
33. Fayek M, Kingsbury SJ, Zada J, et al. Psychopharmacology: cardiac effects of antipsychotic medications. Psychiatr Serv 2001 ;52:607-609
34. Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997;4: 159-177
35. Beasley CM, Grundy SL, Gannon KS, et al. Overview of the safety of olanzapine. In: Tran PV, Bymaster FP, Tye N, et al, eds. Olanzapine (Zyprexa): A Novel Antipsychotic. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:280-299
36. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry 2000;57:968-976
37. Cummings JL, Mega M, Ray K, et al. The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314
38. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
39. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-849
40. Baker RW, Tohen M, Milton D, et al. Olanzapine versus divalproex for the treatment of acute mania [abstract]. Schizophr Res 2001;49(suppl 1-2): 220
41. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158: 131-134
42. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
43. Kinon BJ, Roychowdhury SM, Milton DR, et al. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001;62(suppl 2):17-21
44. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia. Arch Gen Psychiatry 1998;55:250-258
45. Purdon SE, Jones BDW, Slip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-258
46. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
47. Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505
48. Beasley CM Jr, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizo-phrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30
49. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-281
50. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000;61 (suppl 4):27-32
51. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000;17:363-384
52. Sajatovic M, Perez D, Brescan D, et al. Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol Bull 1998;34:819-823
53. Eastham JH, Jeste DV. Treatment of schizophrenia and delusional disorder in the elderly. Eur Arch Psychiatry Clin Neurosci 1997;247:209-218
54. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999;7:70-76
55. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8:52S-56S
56. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220
57. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends. 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47
58. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472
59. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
60. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149: 689-690
61. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149:68-72
62. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100
63. Breier A, Tanaka Y, Roychowdhury S, et al. Nizatidine for the prevention of olanzapine-associated weight gain in schizophrenia and related disorders: a randomized controlled double blind study. Presented at a meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP): March 25,2001; San Antonio, Tex
64. Axid (nizatidine). Physicians' Desk Reference. Montvale, NJ: Medical Economics: 2001:1704-1706
65. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
66. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11:25-32
67. Meyer JM. One-year comparison of lipids, glucose, and weight with olan-zapine or risperidone. In: New Research Abstracts of the 154th Annual Meeting of the American Psychiatric Association; May 9, 2001; New Orleans, La. Abstract NR490:133
68. Casey DE, Danielson EM, Fishman NB. Prevalence of diabetes in schizophrenia patients treated with antipsychotics. In: New Research Abstracts of the 154th Annual Meeting of the American Psychiatric Association; May 8, 2001; New Orleans, La. Abstract NR315:85-86
69. Sernyak MJ, Rosenheck RA, Leslie D. Association of diabetes mellitus with atypical neuroleptics. In: New Research Abstracts of the 154th Annual Meeting of the American Psychiatric Association; May 9, 2001; New Orleans, La. Abstract NR506:137-138
70. Mukherjee S. High prevalence of type II diabetes in schizophrenic patients. Schizophr Res 1995;37:68-73
71. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-912
72. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73
73. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999;22:1002-1003
74. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443
75. Lindenmayer JP, Patel R. Olanzapine induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999;9:1471
76. Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 2001;138:936-938
77. Keskiner A, el-Toumi A, Bousquet T. Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics 1973;14:176-181
78. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia: a preliminary study. J Clin Hosp Pharmacy 1986;11:297-299
79. Beasley CM Jr, Kwong K, Berg PH, et al. Incidence and rate of treatmentemergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Presented at the 30th annual meeting of the American College of Neuropsychopharmacology; Dec 12, 2000; San Juan, Puerto Rico
80. Kinon BJ, Milton DR, Hill AL, et al. Efficacy of Zyprexa Zydis in the treatment of acutely ill, noncompliant schizophrenic patients. In: New Research Abstracts of the 154th Annual Meeting of the American Psychiatric Association; May 8, 2001; New Orleans. La. Abstract NR281:76
81. Wright P, Birkett M, Ferchland I, et al. A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Eur Neuropsychopharmacol 2000;10:S304
82. Meehan K, Breier A, David SR, et al. Efficacy and safety of intramuscular (IM) olanzapine versus IM lorazepam and IM placebo in acutely agitated patients diagnosed with mania associated with bipolar disorder [abstract]. Schizophr Res 2001;49:239
83. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000;61:833-840